Tumor necrosis factor (TNF) acts as a potent enhancer of granulocyte-macrophage colony-stimulating factor (GM-CSF)-and interleukin-3 (IL-3)-induced human acute myeloid leukemia (AML) growth in vitro. We have analyzed the effects of TNFa on the expression of GM-CSF and IL-3 receptors on AML cells. Incubation of blasts from seven patients with AML in serum-free medium with TNF (lo3 U/mL) and subsequent binding studies using show that TNF increases the specific binding of GM-CSF (30% t o 280%) and IL-3 (40% t o 600%) in all cases. From Scatchard plot analysis it appears that TNF upregulates (1) low-affinity GM-CSF binding sites, (2) common high-affinity IL-3/GM-CSF binding sites, and (3) unique (non-GM-CSF binding) IL-3 binding sites. The effect of TNF is dose dependent and is half maximal at a concentration of 100 U/mL, and becomes evident at 18 hours of incubation with TNF at 37°C. but not at 0°C. The UMOR NECROSIS factor a (TNFa) is a polypeptide T with multiple biologic activities, including effects on hematopoiesis.' Macrophages are the major cellular sources of TNFCX.'.~ TNFa may inhibit proliferation of hematopoietic progenitor cells from normal subjects and influence the efficiency of growth of human le~kemia.4.~ Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) belong to the group of CSFs that regulate proliferation and differentiation of relatively primitive hematopoietic precursor cells.8-'' GM-CSF and IL-3 are potent stimulators of proliferation of human acute myeloid leukemia (AML) in ~itro.'*~'~ TNF acts synergistically with the stimulative effects of GM-CSF'6.'7 and IL-3I7 on AML proliferation in vitro, but may depress G-CSFmediated AML growth in vitro.I7 The mechanism of enhancement of GM-CSF-or IL-3-induced AML cell growth by TNF is unknown.
T with multiple biologic activities, including effects on hematopoiesis.' Macrophages are the major cellular sources of TNFCX.'.~ TNFa may inhibit proliferation of hematopoietic progenitor cells from normal subjects and influence the efficiency of growth of human le~kemia. 4 .~ Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) belong to the group of CSFs that regulate proliferation and differentiation of relatively primitive hematopoietic precursor cells.8-'' GM-CSF and IL-3 are potent stimulators of proliferation of human acute myeloid leukemia (AML) in ~itro.'*~'~ TNF acts synergistically with the stimulative effects of GM-CSF'6.'7 and IL-3I7 on AML proliferation in vitro, but may depress G-CSFmediated AML growth in vitro.I7 The mechanism of enhancement of GM-CSF-or IL-3-induced AML cell growth by TNF is unknown.
Here we present studies that were concerned with the question as to whether the TNF effects might be accomplished at the level of membrane receptors. The results of these experiments indicate that TNF upregulates the expression of GM-CSF and IL-3 receptors on AML blasts. These observations may provide a plausible explanation for the synergistic relationship between TNFa and GM-CSFIIL-3 with regard to stimulation of growth in vitro.
MATERIALS AND METHODS
Patients and purification of AML blasts, normal granulocytes, and monocytes. AML blasts were isolated from the peripheral blood and the bone marrow of seven adult untreated AML cases that were classified as M1 (n = 3), M4 (n = 2), and M5 (n = 2)."," Approval was obtained from the Institutional Review Board for these studies. Patients were informed that blood samples were obtained for research purposes, and that their privacy will be protected. AML blasts were separated after Ficoll-Isopaque centrifugation and subsequent removal of E-rosette-forming cells, and then cryopreserved."' Monocytes were removed from the AML cell preparation by plastic adherence. Morphologic examination of cytospin slides of the final cell suspension showed that more than 98% of the cells were blasts. Granulocytes were obtained from the GM-CSF dose-response curve of AML-colony-forming units plateaus at a higher level in the presence of TNF, which indicates that additional numbers of cells become responsive t o GM-CSF. Incubation of AML blasts with the phorbol ester 12-0-tetradecanoylphorbol-13-acetate or formyl-Met-LeuPhe (protein kinase C activators) does not influence GM-CSF receptor expression, suggesting that receptor upregulation by TNF is not mediated through activation of protein kinase C. On the other hand, the protein synthesis inhibitor cycloheximide abrogates receptor upregulation induced by TNF. In contrast t o these findings in AML, TNF does not upregulate GM-CSF receptor numbers on blood granulocytes or monocytes. We conclude that TNF exerts positive effects on growth factor receptor expression of hematopoietic cells.
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blood of healthy volunteers after sedimentation in 0.1% methycellulose, and subsequent Ficoll-Isopaque centrifugation. The resulting cell fractions consisted of neutrophils (92% to 96%), eosinophils (2% to 5%), and mononuclear cells (3% to 5%). Monocytes (more than 80%) were obtained from the Ficoll-Isopaque interphase of mononuclear cells with subsequent removal of E-rosetting cells.
Before the binding experiments, AML cells, granulocytes, or monocytes were washed twice in Hank's balanced salt solution (HBSS), then incubated with TNF (lo' U/mL) in serum-free medium" at 37°C for 1, 2, 4, 8, and 18 hours (for AML cells), 18 hours (for monocytes), or 10 to 60 minutes (for granulocytes). The cells were then washed in sodium citrate (pH 4) to remove cell-bound TNF." Before and after the latter acid wash, the cells were washed twice in HBSS.
Treatment of AML blasts with fMLP, TPA, and cycloheximide. AML cells (case 7) were incubated in serum-free medium for 18 hours at 37°C without or with TNF (see above). In parallel, blasts were also exposed to protein kinase C (PKC) activators. The phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA; Sigma Co, St Louis, MO) was applied at 10 nmol/L, and formyl-Met-LeuPhe (fMLP; Sigma) was added at 1 pmol/L. Analogue incubations were performed with varying concentrations of cycloheximide (0.25,0.5, and 1 pg/mL). After incubation, the cells were washed in sodium citrate (pH 4). Before and after the acid wash, the cells Cells from seven AML cases were incubated with or without TNF for 18 hours before the radiolabeling studies ~singl~~l-GM-CSF or 1251-IL-3. Parallel experiments were performed also for nonincubated cells. Values refer to the mean specific binding 2 SD (in cpm) of triplicate estimations. Values were corrected for nonspecific binding. The specific activities for '251-GM-CSF and 1251-1L*3 were 6.1 x IO4 and 4.4 x lo4 cpm/ng, respectively. Abbreviation: ND, not done.
were washed twice in HBSS and subsequently used in radiolabeling studies.
Recombinant human GM-CSF (rhGM-CSF, CHO-cell derived; glycosilated, molecular weight [mol wt] 25 Kd) was prepared and purified at Genetics Institute (Cambridge, MA). rhIL-3 (Yersinia derived; nonglycosilated, mol wt 15 Kd) was prepared and purified at Gist Brocades (Delft, The Netherlands). Both proteins were radiolabeled with Bolton and Hunter reagent (Amersham Laboratory, Amersham, UK)" as described.24 Specific activities as determined by selfdisplacement analysis2' were 5 to 7 x lo4 c p d n g for radioiodinated GM-CSF ("'I-GM-CSF) and 3 to 6 x lo4 cpm/ng for '=I-IL-3. Trichloroacetic acid precipitation showed less than 5% nonprecipitable radioactivity for both factors. The maximum binding capacity was estimated at 90% to 95% for GM-CSF and 55% to 60% for IL-3. In Scatchard calculations the free cpm were corrected for the maximum binding capacity.26
Binding of radiolabeled GM-CSF and IL-3 to AML blasts, granulocytes, and monocytes. GM-CSF and IL-3 binding to the cells was assessed as de~cribed?~ Equilibrium binding conditions for both GM-CSF and IL-3 at 37°C were reached after 1 Cells, 1 to 8 x loh, were incubated for 1 hour at 37°C in 100 WL a minimal essential medium with 1% bovine serum albumin. Initial binding experiments were performed using two concentrations (1 or 2 nmol/L) of "'I-GM-CSF or I2'I-IL-3. To allow estimation of both high-and low-affinity GM-CSF receptor numbers and affinities on AML cells, complete binding assays with titrated concentrations of I2'I-GM-CSF (20 to 5,000 pmol/L) were performed. Binding experiments with 1Z51-GM-CSF were also performed in the presence of excess concentrations of nonlabeled IL-3 (see Table 3 ). Results from these experiments represent low-affinity binding of GM-CSF alone, because IL-3 selectively competes for the highaffinity binding of GM-CSF'" (the common IL-3IGM-CSF binding site). For a complete IL-3 binding assay, 20 to 2,000 pmolIL "'I-IL-3 was used. Nonspecific binding was determined in parallel incubations in the presence of excess (ie, 200 nmol/L) unlabeled GM-CSF or IL-3. Specific binding was defined as the difference between the amount of radioactivity bound in the absence of nonlabeled factor and the amount of radioactivity bound in the presence of nonlabeled factor. To distinguish the two different IL-3 binding sites that have been described," excess concentrations of nonlabeled GM-CSF were used in binding experiments performed with I2'1-IL-3. The common IL-3/GM-CSF binding sites were defined as sites that bind lZsI-IL-3 which are competed for by unlabeled GM-CSF. The unique IL-3 binding sites are those that remain detectable with IzI-IL-3 after competition with GM-CSF.2X All experiments were conducted in duplicate. Samples were counted in a gamma-counter (Packard, Downers Grove, IL). The
Radioiodination of GM-CSF and IL-3.
counting efficiency for I2' I was 80%. Receptor numbers and binding affinities were estimated by Scatchard analyskz6 Two affinity receptor analyses were performed with the Enzfitter computer program (Sigma).
The dose-response curve of GM-CSF was established in the presence and absence of TNF for the clonogenic cells of two AML cases (nos. 4 and 6 ) . In these experiments, lo5 AML cells were plated in serum-free colony culture (1 mL) with 0.9% methylcell~losel~ supplemented with variable concentrations of GM-CSF (0.01,0.03,0.1,0.3, 1,3,10,30, 100,300, and 1,000 UlmL). All aggregates of 10 cells or more were scored after 14 days.
AML clonogenic assay.

RESULTS
TNF upregulates high-and low-afinity binding sites of GM-CSF on AML blasts. The AML blasts from seven cases were cultured for 18 hours with TNFa (lo3 U/mL). Subsequent incubation of the cells with 1 nmol/L Iz5I-GM-CSF demonstrated that TNF had augmented specific GM-CSF binding to cells from all seven cases (Table 1) as compared with the cells incubated without TNF or preculture cells. The increase of specific binding ranged from 31% For (case 6) to 281% (case 1). In four cases (nos. 4 through 7), AML blasts that were cultured for 18 hours without TNF also expressed greater GM-CSF binding as compared with precultured cells (Table 1 ). Binding assays with titrated concentrations of lzI-GM-CSF showed that, after TNF exposure, both high-and low-affinity GM-CSF binding sites increased considerably (Table 2 , Fig 1) . The TNFdependent increase of low-affinity GM-CSF receptor numbers on AML blasts was also apparent in separate binding experiments performed after the blockade of high-affinity GM-CSF binding in the presence of an overdose of nonlabeled IL-3 (200 nmol/L) ( Table 3) ." Upregulation of GM-CSF receptors appeared TNF dose dependent with a maximal effect at approximately 300 U/mL (Fig 2) . In separate experiments, AML cells were incubated with TNF for varying time intervals (1, 2, 4, 8, and 18 hours). The increase of GM-CSF binding induced by TNF became expressed after 18 hours (not shown). In control experiments, the effects of TNF on the expression of GM-CSF binding to granulocytes as well as monocytes were investigated. As observed previously? TNF was found to downregulate GM-CSF receptor expression on granulocytes (Table  2) . On the other hand, TNF under identical conditions did not affect GM-CSF receptor expression on monocytes ( Table 2) . TNF upregulates high-afinity binding sites of IL-3 on AML blasts. Preliminary binding studies showed that TNF also increased the specific binding of '"I-IL-3 to AML cells in six of seven cases ( Table 1 ). The increase of specific binding of '"I-IL-3 ranged from 44% to 628%. From a complete binding assay with titrated concentrations of lz51-IL-3 with Fig 3) , it was evident that IL-3 receptor numbers had increased as compared with the values following the control incubation in the absence of TNF. Cross-competition with excess nonlabeled GM-CSF showed that both the unique IL-3 binding sites as well as the common IL-3/GM-CSF binding sitesz were upregulated by TNF (Fig 3) . The average numbers of unique IL-3 binding sites increased from 90 sites per cell to 262 sites per cell (kd 261 pmol/L). The numbers of common IL-3/GM-CSF binding sites calculated by subtraction of unique IL-3 receptor numbers from total IL-3 binding sites increased from 175 sites per cell toward 340 sites per cell.
Upregulation of GM-CSF receptor expression by TNF is not dependent on PKC activation. Downregulation of the expression of GM-CSF receptors on neutrophils by TNF, as was recently shown," is probably mediated through activation of PKC3' To investigate whether the upregulation of GM-CSF receptors on AML cells is also mediated via activation of PKC, the blasts were exposed to the PKC activators TPA or fMLP. Neither TPA nor fMLP, at concentrations that downregulate GM-CSF receptors on neutrophils, elevated the numbers of GM-CSF receptors on AML blasts (Fig 4A) .
GM-CSF receptor upregulation is blocked by cycloheximide. We further examined whether the increase in GM-CSF receptor numbers after incubation of the AML cells with TNF required active protein synthesis. The addition of the protein-synthesis inhibitor cycloheximide at concentrations of 0.25 to 1 &mL did not affect GM-CSF binding in the absence of TNF (Fig 4B) . However, at these concentra- Cells from AML cases 4, 5, and 6 were incubated without or with TNF for 18 hours before radiolabeling studies using '251-GM-CSF (1 nmol/L).
Comparative experiments were performed with nonincubated cells. Values refer to the means of triplicate estimates of specific binding f SD (in cpm)
in the presence or absence of excess nonlabeled IL-3 (200 nmol/L). Values were corrected for nonspecific binding (20% to 30% of the total binding).
The specific activity of '251-GM-CSF was 5.2 x lo4 cpm/ng.
*Indicates the sum of high-and low-affinity binding of lZ51-GM-CSF (without IL-3 competition).
tlndicates low-affinity binding of '251-GM-CSF (with IL-3 competition).
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From tions, cycloheximide prevented the increase of GM-CSF binding induced by TNF. The spontaneous increase in GM-CSF binding after 18 hours of incubation, which was seen in four cases of AML, was not suppressed by cycloheximide (Fig 4B) .
Altered GM-CSF dose-response relationship ofAML colonyforming cells as the consequence of TNF addition. Using titrated GM-CSF concentrations, we established the effect of TNF on AML colony formation. The results (Fig 5 ) show that there was no change in the sensitivity to GM-CSF as a result of the addition of TNF. TNF did not shift the dose-response curve to the left. Instead, TNF was found to increase the plateau of GM-CSF stimulation, indicating the ELBAZ ET AL AML cells were incubated with or without TNF for 18 hours. This was followed by IL-3 radioreceptor analysis. Receptor numbers (mean per cell) and kd were derived from Sctachard plot analysis. (+) Indicates that specific binding was detectable but values were too low to permit complete Scatchard analysis.
recruitment of greater cell numbers into proliferation at maximal GM-CSF concentrations.
DISCUSSION
TNF is a regulator of surface expression of hematopoietic growth factor receptors. It downregulates the expression of GM-CSF receptorsz9 and G-CSF receptors on granulocytes,3° as well as M-CSF receptors on macrophages." In this study, we investigated the effects of TNF on GM-CSF and IL-3 receptors on AML blasts. It is evident from the results of these experiments (Tables 1 and 2 , and Fig 1) that TNF augments the average level of GM-CSF receptors on AML blasts by approximately twofold. The increase of receptor numbers after TNF exposure is accomplished within approximately 18 hours. Both the high-affinity and low-affinity binding sites of GM-CSF increase on these cells (Tables 2 and 3, Fig 1) . In a recent study, high-affinity IL-3/GM-CSF binding sites, which can bind both IL-3 and GM-CSF, and IL-3-specific high-affinity binding sites have been distinguished on human AML blasts.% It appears from the results presented here that TNF upregulates both high-affinity receptors, ie, GM-CSF/IL-3 and IL-3 binding sites (Fig 3 and Table 4) . Upregulation of GM-CSF, IL-3, and common GM-CSF/IL3 receptors is not associated with an apparent change in receptor affinities.
Receptor upregulation by TNF might result in a positive effect of TNF on IL-3-or GM-CSF-mediated AML cell growth. Recent findings have shown that TNF enhances DNA synthesis and colony formation of AML blasts after stimulation with GM-CSF or IL-3." Cells that initially express no or subliminal levels of growth factor receptors may become responsive to IL-3 and GM-CSF after TNF exposure. This would imply that additional subpopulations are triggered to proliferate and that the sensitivity of the cells to GM-CSF or IL-3 has remained constant. The change of the GM-CSF dose-response curve of proliferating AML cells as the consequence of TNF supplementation is in accordance with this conclusion. GM-CSF dose dependence of AML-colony-forming units (Fig 5 ) or actively DNA synthesizing cells (data not shown) is not shifted to the left in the presence of TNF, being indicative of the same sensitivity of stimulation. In fact the maximal level of stimulation is elevated to a higher plateau. Recently, analogous with the results in human AML, it was observed that IL-3 and TNF or GM-CSF and TNF synergize in stimulating the colony formation of purified normal bone marrow blast cells as well.32 Receptor upregulation could also provide a plausible explanation for IL3/TNF or GM-CSF/TNF synergistic growth activation of normal hematopoietic progenitors. We assume that in vitro IL-3 and GM-CSF receptor upregulation by TNF may be a feature of leukemic as well as normal hematopoiesis. The exact mechanism of receptor upregulation by TNF presently remains unresolved. However, the observations that the increase of GM-CSF and IL-3 receptors requires an incubation of approximately 18 hours and is inhibitable by cycloheximide suggest that the effect of TNF depends on active protein synthesis. The negative effects of TNF on the expression of GM-CSF and G-CSF receptors on neutrophils and M-CSF receptors on monocytes appear to be mediated through activation of PKC.29-31 The studies presented here do not support the idea that PKC is similarly involved in receptor upregulation. The PKC activators TPA and fMLP did not influence GM-CSF receptor values ( Fig  4A) . It is unlikely that improved survival of AML blasts in vitro as the result of TNF exposure would explain the effects of TNF, because exposure of the cells to GM-CSF or M-CSF for 18 hours (not shown) has no effect on GM-CSF or IL-3 receptor expression. The spontaneous increase of GM-CSF receptor numbers in some AML cases in this study is unlikely caused by endogenous TNF production by AML cells33,34 and subsequent activation of new protein synthesis, as cycloheximide has no effect on this increase (Fig 4B) .
The indirect growth-promoting effects of TNF in hematopoiesis have, until recently, been attributed to the pleiotropic capacity of TNF to induce the release of certain hematopoietic growth factors from endothelial cells, mono- 34. Delwel R, van Buitenen C, Salem M, Oosterom R, Touw I, Lijwenberg B: Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-alpha which synergizes with IL-3 and granulocyte-macrophage colony stimulating factor. Leukemia 4557, 1990 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
